| Vol. 14.28 – 5 August, 2022 |
| |
|
|
| The authors identified β-hexosaminidase, a conserved enzyme across commensals of the Bacteroidetes phylum, as a driver of CD4IEL differentiation. [Science] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| A new kind of carrier-free nanoparticle was developed to simultaneously deliver chemotherapeutic drug, cytolytic peptide, and anti-TOX small interfering RNA using a fluorinated prodrug strategy. [Advanced Materials] |
|
|
|
| The authors reported the combined use of a CD28 superagonist and anti–glucocorticoid-induced tumor necrosis factor receptor–related protein monoclonal antibody (G3c) to induce Tr1 cells in vivo. [Science Advances] |
|
|
|
| Investigators demonstrated that MALT1 splicing depended on RNA structural elements that sequestered the splice sites of the alternatively spliced exon7. [Science Advances] |
|
|
|
| The authors identified regulatory T cells as central regulators of the fibroinflammatory reaction by a selective depletion of FOXP3-positive cells in a transgenic mouse model of experimental chronic pancreatitis. [Nature Communications] |
|
|
|
| The metabolic reprogramming linked to M2 macrophage polarization relied on Elp3 and the translation of multiple candidates, including the mitochondrial ribosome large subunit proteins Mrpl3, Mrpl13, and Mrpl47. [EMBO Journal] |
|
|
|
| T cell-specific deletion of CRAC channel genes in mice showed that Orai1, Stim1, and Stim2-deficient T cells had quantitatively distinct defects in store-operated Ca2+ entry , which correlated with gradually more pronounced impairment of cytokine production by Th1 and Th17 cells and the severity of inflammatory bowel disease. [EMBO Molecular Medicine] |
|
|
|
| To identify limitations imposed by imatinib on the antitumor immune response, investigators performed bulk RNA sequencing, single-cell RNAseq, and flow cytometry to phenotype CD8+ T cell subsets in a genetically engineered mouse model of gastrointestinal stromal tumor. [Cancer Immunology Research] |
|
|
|
| Researchers designed and developed a novel 2+1 epidermal growth factor receptor variant III (EGFRvIII)-T cell bispecific antibodies with optimal pharmacological characteristics and potent anti-tumor activity. [Molecular Cancer Therapeutics] |
|
|
|
| Scientists investigated whether human umbilical cord mesenchymal stem cells derived extracellular vesicles could regulate abnormal immune responses of T cells or B cells in systemic lupus erythematosus. [Scientific Reports] |
| |
|
|
|
| Investigators focus on the control of the immune response by regulatory T cells and describe the counteracting processes that preserve their identity under inflammatory challenges. [Immunological Reviews] |
|
|
|
| Tregs regulate homeostasis within the immune system and self-immune tolerance, and play a crucial role in skeletal muscle repair and regeneration. [Cell Death & Disease] |
|
|
|
| The authors discuss studies investigating Treg immunobiology in B cell lymphoid malignancies, focusing on clinical correlations, mechanisms of accumulation, phenotype, and function. [Frontiers in Immunology] |
|
|
|
|
| Gilead Sciences, Inc. and MiroBio, abiotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MiroBio for approximately $405 million in cash. [Gilead Sciences, Inc.] |
|
|
|
| Sanofi and Innovent Biologics announced a collaboration to bring innovative medicines to patients in China with difficult-to-treat cancers. This strategic partnership demonstrates Sanofi and Innovent’s commitment to bringing high quality oncology medicines to patients in China. [Sanofi] |
|
|
|
|
| October 7 – 10, 2022 Beaver Run Resort, Colorado, United States |
|
|
|
|
|
| Columbia University – New York, New York, United States |
|
|
|
| Essen University Hospital – Essen, Germany |
|
|
|
| King’s College London – London, United Kingdom |
|
|
|
| The University of British Columbia – Vancouver, British Columbia, Canada |
|
|
|
| Gilead Sciences, Inc. – Foster City, California, United States |
|
|
|
|